Case Report: PD-1 Blockade Combined Autologous Hematopoietic Stem Cell Transplantation With Modified BEAM Regimen Containing High-Dose Cytarabine to Treat R/R Hodgkin's Lymphoma

Xiaoqi Wang; Kaniel Cassady; Zhongmin Zou; Xi Zhang; Yimei Feng

doi:10.3389/fmed.2021.693023

Case Report: PD-1 Blockade Combined Autologous Hematopoietic Stem Cell Transplantation With Modified BEAM Regimen Containing High-Dose Cytarabine to Treat R/R Hodgkin's Lymphoma

Front Med (Lausanne). 2021 Jul 7:8:693023. doi: 10.3389/fmed.2021.693023. eCollection 2021.

Authors

Xiaoqi Wang¹, Kaniel Cassady², Zhongmin Zou³, Xi Zhang¹, Yimei Feng¹

Affiliations

¹ Medical Center of Hematology, The Xinqiao Hospital of Third Military Medical University, Chongqing, China.
² Irell and Manella Graduate School of Biological Sciences of City of Hope, Duarte, CA, United States.
³ Department of Chemical Defense Medicine, School of Military Preventive Medicine, Third Military Medical University, Chongqing, China.

Abstract

The emergence of new drugs has provided additional options in the treatment of relapsed and refractory (R/R) Hodgkin's lymphoma (HL). However, the use of autologous stem cell transplantation (ASCT) has not been completely replaced in this setting. The use of anti-programmed death-1 (PD-1) antibody bridging to ASCT and as maintenance after transplantation is a novel approach in HL treatment. In this case, we report that PD-1 monoclonal antibody (mAb) plus ASCT with modified BEAM regimen (carmustine + etoposide + cytarabine + melphalan) containing high-dose cytarabine to treat R/R HL may represent a promising regimen in this difficult-to-treat setting.

Keywords: Hodgkin's lymphoma; PD1; autologous stem cell transplantation; beam; case report.

Publication types

Case Reports